More about

Ibrutinib

News
June 19, 2023
3 min watch
Save

VIDEO: Alliance study shows two-drug combination has better results than three in CLL

VIDEO: Alliance study shows two-drug combination has better results than three in CLL

In this video, Michael Choi, MD, discusses the results of the phase 3 Alliance study, pertaining to chronic lymphocytic leukemia, presented at ASCO Annual Meeting.

News
June 14, 2023
2 min read
Save

Venetoclax regimen not superior to standard therapy alone for older patients with CLL

Venetoclax regimen not superior to standard therapy alone for older patients with CLL

CHICAGO — The addition of venetoclax to ibrutinib and obinutuzumab did not extend PFS among older patients with treatment-naive chronic lymphocytic leukemia during the COVID-19 pandemic, according to data presented at ASCO Annual Meeting.

News
April 07, 2023
1 min read
Save

Ibrutinib indications for mantle cell, marginal zone lymphoma to be voluntarily withdrawn

Ibrutinib indications for mantle cell, marginal zone lymphoma to be voluntarily withdrawn

Janssen and Pharmacyclics intend to voluntarily withdraw the U.S. indications of ibrutinib for certain patients with lymphoma, according to a press release.

News
February 27, 2023
3 min read
Save

BLOG: Therapeutic landscape for steroid-refractory chronic GVHD continues to evolve

BLOG: Therapeutic landscape for steroid-refractory chronic GVHD continues to evolve

Chronic graft-versus-host disease continues to be a leading cause of late morbidity and mortality, complicating approximately 35% to 50% of allogeneic transplantations.

News
January 19, 2023
1 min read
Save

FDA approves Brukinsa for chronic lymphocytic leukemia, small lymphocytic lymphoma

FDA approves Brukinsa for chronic lymphocytic leukemia, small lymphocytic lymphoma

The FDA approved zanubrutinib for treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma.

News
December 13, 2022
2 min read
Save

Zanubrutinib prolongs PFS with fewer cardiac events vs. ibrutinib in advanced CLL, SLL

Zanubrutinib prolongs PFS with fewer cardiac events vs. ibrutinib in advanced CLL, SLL

NEW ORLEANS — Zanubrutinib significantly prolonged PFS compared with ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, results of the phase 3 ALPINE study showed.

News
December 10, 2022
3 min read
Save

Ibrutinib could become new standard for first-line treatment of mantle cell lymphoma

Ibrutinib could become new standard for first-line treatment of mantle cell lymphoma

NEW ORLEANS — Patients with newly diagnosed mantle cell lymphoma who received ibrutinib with a standard-of-care regimen had higher failure-free survival rates than those who received standard-of-care treatment alone.

News
August 24, 2022
1 min read
Save

FDA approves Imbruvica for children with chronic graft-versus-host disease

FDA approves Imbruvica for children with chronic graft-versus-host disease

The FDA approved ibrutinib for children with chronic graft-versus-host disease.

News
June 03, 2022
3 min read
Save

Ibrutinib regimen extends PFS for older adults with mantle cell lymphoma

Ibrutinib regimen extends PFS for older adults with mantle cell lymphoma

CHICAGO — A novel first-line regimen significantly improved PFS compared with standard chemoimmunotherapy for older patients with mantle cell lymphoma, according to randomized phase 3 study results presented at ASCO Annual Meeting.

News
April 29, 2022
2 min read
Save

Ibrutinib shows promise for children with chronic graft-versus-host disease

Ibrutinib shows promise for children with chronic graft-versus-host disease

SALT LAKE CITY — Ibrutinib appeared safe and effective for children with previously untreated or relapsed/refractory chronic graft-versus-host disease, according to study results.

View more